Objective To establish a new chemiluminescence method for determination of resorcinol in wastewater. Methods In media of acid chemiluminescence reaction of resorcinol with ceriumⅣ in the presence of Tween 40 as enhancer was investigated. A new chemiluminescence method for determination of resorcinol with flow injection technique was developed. Results The linear range for resorcinol was 8.0?10-8～5.0?10-5 mol/L with 6.0?10-8 mol/L detection limit. The relative standard deviation was 3.5% for 5.0?10-6 mol/L resorcinol in 11 parallel measurements. Conclusion This method can used to determine the content of resorcinol in wastewater of laboratory and resorcinol compound solution with satisfactory results.

OBJECTIVE: The STR genotypping of trace oral epithelial cells which are microdissected by laser capture microdissection system (LCM) is explored. METHODS: The oral epithelial cells are microdissected using a low-power infrared laser by VERITAS Microdissection Instrument. STR loci of Profiler Plus are detected by multiplex PCR procesures. RESULTS: DNA genotyping of 7-8 oral epithelial cells are succeeded, and DNA genotyping of 3-4 oral epithelial cells are failed. CONCLUSION It is viable in genotyping of trace oral epithelial cells by Laser Capture Microdissection as a new technology of seperating single cell.
Cell Separation/methods* ; DNA/genetics* ; Epithelial Cells ; Genotype ; Humans ; Lasers ; Microdissection/methods* ; Mouth/cytology* ; Tandem Repeat Sequences

OBJECTIVETo investigate the clinicpathologic features and diagnosis of plasmablastic lymphoma (PBL).

METHODSEleven cases of PBL were collected and followed up, with review of the literature. HIV and EBV status and their relationships with the tumor were specially compared as well.

RESULTSIn the current cohort, 10 patients were serologically HIV negative; the male to female ratio was 8 to 3, and the median age was 57 years. Ten cases showed extranodal involvement and one case was nodal based. At presentation, five patients had mid-facial involvement, including sinonasal area (3 cases) and oral cavity (2 cases). Histologically, six were PBL of oral mucosa type, and five were PBL with plasmacytic differentiation. In all cases, the neoplastic cells expressed CD138 and MUM-1, and were negative for CD20 and CD3ε; the median Ki-67 index was 80%. Five cases were EBER1/2 in situ hybridization positive. IgH or/and Igκ gene rearrangement was detected in all five cases examined.

CONCLUSIONSMost patients were no congenital or acquired immunodeficiency in the retrospective study. Of the died patients, EBER1/2 in situ hybridization were negative and their disease staging were Ⅳ, The neoplastic cells were immunoblastic or plasmablastic, sometimes the plasmacytoid cell can be seen and the neoplastic cell had mature plasma cell phenotype, the pathologic diagnosis of the lymphoma is still controversial now. Differentiate with plasma cell neoplasm is difficult, it is necessary to accumulate more cases for advanced study and observation in the future.

Female ; Gene Rearrangement ; Humans ; In Situ Hybridization ; Male ; Middle Aged ; Multiple Myeloma ; Plasma Cells ; Plasmablastic Lymphoma ; diagnosis ; pathology ; RNA, Viral ; metabolism ; Retrospective Studies

OBJECTIVETo evaluate the expression and clinical significance of Endostatin, vascular endothelial growth factor (VEGF) and fibroblast growth factor basic-2 (FGF-2) in the laryngeal squamous cell carcinoma (LSCC).

METHODSThe expression of Endostatin, VEGF and FGF-2 in 50 specimens of LSCC, 40 specimens of para-carcinoma and 10 specimens of normal laryngeal tissues were examined by Flow cytometry.

RESULTSCompared with para-carcinoma and normal laryngeal tissues, the expression level and positive rate of Endostatin, VEGF, FGF-2 in LSCC were different in statistics (P < 0.05); the expression level and positive rate of endostatin, VEGF, FGF-2 in LSCC are obviously higher than those in para-carcinoma and normal laryngeal tissues. The expression level and positive rate of Endostatin, VEGF, FGF-2 were no difference in statistics between para-carcinoma and normal laryngeal tissues (P > 0.05). The expression level and positive rate of Endostatin, VEGF, FGF-2 in LSCC were associated with lymphoid metastasis and clinical stage, not associated with age, sex and clinical group.

CONCLUSIONSEndostatin, VEGF and FGF-2 play important role in the incidence, development and prognosis of the LSCC.

Adult ; Aged ; Carcinoma, Squamous Cell ; metabolism ; pathology ; Endostatins ; metabolism ; Female ; Fibroblast Growth Factor 2 ; metabolism ; Gene Expression Regulation, Neoplastic ; Humans ; Laryngeal Neoplasms ; metabolism ; pathology ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Vascular Endothelial Growth Factor A ; metabolism

OBJECTIVETo explore clinical significance of monitoring the level of minimal residual disease (MRD) at different time point in the risk stratification and prognosis of Childhood B-lineage Acute Lymphoblastic Leukemia.

METHODSThree hundred and eighty cases of children's B-ALL from Augest 2008 to January 2013 in our hospital were enrolled in this study. MRD levels were detected at day 15, day 33 and week 12 after initial chemotherapy. The event-free survival(EFS) and overall survival (OS) were measured on the basis of MRD levels at different stages of chemotherapy and were compared by Kaplan Meier analyses.

RESULTSThe patient's age, initial white blood cell count, chromosome, MLL, BCR/ABL, pretreatment reaction, bone marrow MRD at days 33 were closely related with the 5-year EFS rate. Multiparameter flow cytometry showed the marked MRD and unmarked MRD were not significantly different between their 5-year EFS rate(P>0.05), and the every immune phenotype was also no significantly different between the 5-year EFS rate(P>0.05). The children with MRD≥10at day 15(P<0.01), MRD≥10at day 33 (P<0.01) and MRD≥10on week 12(P<0.01) have a decreased 5-year EFS rate and overall survival, which related with poor prognosis obviously. The 5-year EFS rates at the MRD<10(negative), 10-10, 10-10and ≥10at day 33 were 86.6±2.7%, 77.5±4.9%, 70.1±8.0%, and 44.8±9.9%(P<0.01) with significant difference respectively; the 5-year OS rate was 89.5±2.7%, 80±4.9%, 76.0±7.8%, and 53.2±10.1% with statistically significant difference(P<0. 01).

CONCLUSIONThe MRD≥10at day 33 is a high risk factor for significant reduction of the 5-year EFS rate and the 5-year OS rate of children with B-ALL. Thus, dynamic monitoring the MRD level can predict relapse of B-ALL after remission.

OBJECTIVEThe study was to analyze the acute heart failure's risk factors and clinical characteristics for the patient with chronic myelogenous leukemia (CML) during the early stage (within 100 d) of allogeneic hematopoietic stem cell transplantation (allo-HSCT).

METHODSA total of 106 cases of CML received allo-HSCT were retrospectively studied in Nanfang Hospital from May 2003 to May 2013. On the basis of existence or absence of acute heart failure during early stage of allo-HSCT (100 d), the patients were divided into heart failure (15 cases) and control group (91 cases). Using Logistic univariate analysis, Fisher' exact test and Pearson X(2) test, the acute heart failure's risk factors and clinical characteristics of both groups were analyzed.

RESULTSThe median occurrence time of acute heart failure was 3 d (1 d before transplantation to 84 d after transplantation). Logistic univariate analysis indicated that the imatinib treatment history and time, and the prophylaxis regimens for GVHD with anti-thymocyte globulin (ATG) were all the poor prognostic factors for acute heart failure. Incidence of hepatic veno-occlusive disease (HVOD), bacterial infection and adverse prognostic events including death in the heart failure group patients were statistically higher than that in control group (P < 0.05).

CONCLUSIONAcute heart failure mostly happened in the early stage after allo-HSCT, imatinib treatment and GVHD prophylaxis regimens with ATG are the poor prognostic factors for acute heart failure. The patients of heart failure group seem to have higher incidence of hepatic veno-occlusive disease (HVOD), bacterial infection and deaths.

Acute Disease ; Allografts ; Antilymphocyte Serum ; Benzamides ; Heart Failure ; Hematopoietic Stem Cell Transplantation ; Hepatic Veno-Occlusive Disease ; Humans ; Imatinib Mesylate ; Incidence ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; Piperazines ; Pyrimidines ; Retrospective Studies ; Risk Factors